- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06274255
Serum Magnesium Level and Pediatric Migraine (Migraine)
Balikesir University, Faculty of Medicine
Aim: The purpose of this study is to compare serum magnesium levels between patients with migraine and a control group and to examine the relationship between the frequency and duration of attacks in patients with migraine and mean serum magnesium levels.
Material-Method: Patients diagnosed presenting to the Balıkesir University Medical Faculty pediatric neurology clinic between 01.09.2019 and 01.04.2023 and diagnosed with migraine were enrolled retrospectively. Patients diagnosed with migraine were included as the study group and healthy children presenting to the pediatric neurology clinic in the same period as the control group. The demographic characteristics (age, sex, and body mass index) of the patient group and their clinical (attack durations and frequencies, symptoms during attacks, and treatments) and laboratory (hemoglobin, hematocrit, platelet, glucose, calcium, magnesium, vitamin D, folate and ferritin levels) characteristics were recorded.
Study Overview
Status
Conditions
Detailed Description
Patients diagnosed presenting to the Balıkesir University Medical Faculty pediatric neurology clinic, Türkiye, between 01.09.2019 and 01.04.2023 and diagnosed with migraine were included retrospectively. The study was approved by the institutional clinical research ethics committee (decision no. 2023/68 dated 10.05.2023).
Patients diagnosed with migraine were included as the study group and healthy children presenting to the pediatric neurology clinic at the same times were enrolled as the control group. The demographic characteristics (age, sex, and body mass index) of the patient group and their clinical (attack durations and frequencies, symptoms during attacks, and treatments) and laboratory (hemoglobin (Hb), hematocrit (Hct), platelet, glucose, calcium (Ca), magnesium (Mg), vitamin D, folate and ferritin levels) characteristics were recorded.
Patients and controls in whom Mg therapy was contraindicated (renal failure or nephrolithiasis), with non-migraine headaches, with substance/drug addiction (abuse), with psychiatric and/or chronic systemic diseases, and cases with histories of drug use (antidepressants, neuroleptics, tranquilizer group, antiepileptic medications (lithium and carbamazepine), using headache prophylaxis (beta blockers and calcium antagonists), and patients with deficient file data were excluded from the study.
Statistical analysis Descriptive characteristics (mean, number, and percentage) were determined for the study variables. Normality of distribution of numerical variables was checked. Whether continuous variables are normally distributed or not was evaluated by Kolmogorov Smirnov. Independent sample t test was used for normally distributed continuous variables. The Kruskal Wallis test was used to determine the difference between the means of three or more groups in non-normally distributed groups. Qualitative data were given as absolute reference and percentage distributions, and quantitative variables as mean and standard deviation (SD) in case of normal distribution. Categorical variables were compared using the chi-square test. Analyses were performed on Statistical Package for Social Sciences version 25 software. p values <0.05 were considered significant.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Aysen Orman, assoc. Dr.
- Phone Number: 2646 +903242410000
- Email: ormanaysen709@gmail.com
Study Contact Backup
- Name: Aysen Orman, assoc. Dr.
- Phone Number: 2646 +905057917405
- Email: ormanaysen709@gmail.com
Study Locations
-
-
Türkiye
-
Balıkesir, Türkiye, Turkey, 33343
- Hilal Aydın
-
Contact:
- Hilal Aydın, assoc. Dr.
- Phone Number: +902666121461
- Email: drhilalaydin@gmail.com
-
Contact:
- Hilal Aydın, assoc. Dr.
- Phone Number: +905072607541
- Email: drhilalaydin@gmail.com
-
Mersin, Türkiye, Turkey, 33343
- Aysen Orman
-
Mersin, Türkiye, Turkey, 33343
- MersinU
-
Contact:
- Aysen Orman
- Email: ormanaysen709@gmail.com
-
Contact:
- Aysen Orman
- Phone Number: 2646 3242410000
- Email: ormanaysen709@gmail.com
-
Mersin, Türkiye, Turkey, 38000
- Aysen Orman
-
Contact:
- Aysen Orman, assoc. Dr.
- Phone Number: +903242410000 +903242410000
- Email: ormanaysen709@gmail.com
-
Principal Investigator:
- Aysen Orman, assoc. Dr.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Patients diagnosed presenting to the Balıkesir University Medical Faculty pediatric neurology clinic, Türkiye, between 01.09.2019 and 01.04.2023 and diagnosed with migraine were included retrospectively. The study was approved by the institutional clinical research ethics committee (decision no. 2023/68 dated 10.05.2023).
Patients diagnosed with migraine were included as the study group and healthy children presenting to the pediatric neurology clinic at the same times were enrolled as the control group. The demographic characteristics (age, sex, and body mass index) of the patient group and their clinical (attack durations and frequencies, symptoms during attacks, and treatments) and laboratory (hemoglobin (Hb), hematocrit (Hct), platelet, glucose, calcium (Ca), magnesium (Mg), vitamin D, folate and ferritin levels) characteristics were recorded.
Description
Inclusion Criteria:
- Patients diagnosed with migraine were included as the study group and healthy children presenting to the pediatric neurology clinic at the same times were enrolled as the control group.
Exclusion Criteria:
- Patients and controls in whom Mg therapy was contraindicated (renal failure or nephrolithiasis), with non-migraine headaches, with substance/drug addiction (abuse), with psychiatric and/or chronic systemic diseases, and cases with histories of drug use (antidepressants, neuroleptics, tranquilizer group, antiepileptic medications (lithium and carbamazepine), using headache prophylaxis (beta blockers and calcium antagonists), and patients with deficient file data were excluded from the study.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Controlle group
healthy children presenting to the pediatric neurology clinic at the same times were enrolled as the control group.
The demographic characteristics (age, sex, and body mass index) of the patient group and their clinical (attack durations and frequencies, symptoms during attacks, and treatments) and laboratory (hemoglobin (Hb), hematocrit (Hct), platelet, glucose, calcium (Ca), magnesium (Mg), vitamin D, folate and ferritin levels) characteristics were recorded.
|
Patients diagnosed with migraine were included as the study group
Patients diagnosed with migraine were included as the study group The demographic characteristics (age, sex, and body mass index) of the patient group and their clinical (attack durations and frequencies, symptoms during attacks, and treatments) and laboratory (hemoglobin (Hb), hematocrit (Hct), platelet, glucose, calcium (Ca), magnesium (Mg), vitamin D, folate and ferritin levels) characteristics were recorded. Patients and controls in whom Mg therapy was contraindicated (renal failure or nephrolithiasis), with non-migraine headaches, with substance/drug addiction (abuse), with psychiatric and/or chronic systemic diseases, and cases with histories of drug use (antidepressants, neuroleptics, tranquilizer group, antiepileptic medications (lithium and carbamazepine), using headache prophylaxis (beta blockers and calcium antagonists), and patients with deficient file data were excluded from the study. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum Magnesium Level and Pediatric Migraine
Time Frame: between 01.09.2019 and 01.04.2023
|
To detect serum magnesium level in migraine attacks in children
|
between 01.09.2019 and 01.04.2023
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum Magnesium Level and Pediatric Migraine
Time Frame: between 01.09.2019 and 01.04.2023
|
Determining serum magnesium level in children with and without migraine
|
between 01.09.2019 and 01.04.2023
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Hilal Aydın, assoc. Dr., Balikesir University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BalikesirU
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine, Magnesium, Pediatric
-
Thomas KrebsCompletedElbow Fracture | Magnesium-based | Bioresrobable Implants | Pediatric Elbow Fractures | Osteosynthesis | Childhood | MagnezixSwitzerland
-
PfizerRecruitingPediatric MigraineUnited States, Spain, Canada, China, Poland, United Kingdom, Mexico, Japan, Sweden
-
Assiut UniversityNot yet recruitingMagnesium | Intraoperative Analgesia
-
University of LjubljanaMasaryk UniversityCompletedMagnesium | Skeletal Muscle Contraction PropertiesCzechia, Slovenia
-
Loma Linda UniversityRecruitingMagnesium Sulfate | Intraoperative Neurophysiological MonitoringUnited States
-
Stanford UniversityCompletedMagnesium Sulfate Pharmacokinetics and PharmacodynamicsUnited States
-
Istanbul UniversityCompletedTransplant Dysfunction | Magnesium DisorderTurkey
-
Menoufia UniversityCompletedIntraperitoneal Magnesium Sulphate in Laparoscope in PediatricsEgypt
-
Hospital Federal de BonsucessoUnknownNeuromuscular Blockade | Magnesium Sulfate | Rocuronium | Deep Neuromuscular BlockadeBrazil
-
Peking University Third HospitalRecruitingDegradation of Magnesium Alloy Prosthesis and New Bone RegenerationChina